Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
31 01 2023
31 01 2023
Historique:
received:
16
05
2022
accepted:
13
09
2022
pubmed:
20
10
2022
medline:
2
2
2023
entrez:
19
10
2022
Statut:
ppublish
Résumé
Blood biomarkers for Alzheimer disease (AD) have consistently proven to be associated with CSF or PET biomarkers and effectively discriminate AD from other neurodegenerative diseases. Our aim was to test their utility in clinical practice, from a multicentric unselected prospective cohort where patients presented with a large spectrum of cognitive deficits or complaints. The MEMENTO cohort enrolled 2,323 outpatients with subjective cognitive complaint (SCC) or mild cognitive impairment (MCI) consulting in 26 French memory clinics. Participants had neuropsychological assessments, MRI, and blood sampling at baseline. CSF sampling and amyloid PET were optional. Baseline blood Aβ42/40 ratio, total tau, p181-tau, and neurofilament light chain (NfL) were measured using a Simoa HD-X analyzer. An expert committee validated incident dementia cases during a 5-year follow-up period. Overall, 2,277 individuals had at least 1 baseline blood biomarker available (n = 357 for CSF subsample, n = 649 for PET subsample), among whom 257 were diagnosed with clinical AD/mixed dementia during follow-up. All blood biomarkers but total tau were mildly correlated with their equivalence in the CSF (r = 0.33 to 0.46, In a clinic-based cohort of patients with SCC or MCI, blood biomarkers may be good hallmarks of underlying pathology but add little to 5-year dementia risk prediction models including traditional predictors.
Sections du résumé
BACKGROUND AND OBJECTIVE
Blood biomarkers for Alzheimer disease (AD) have consistently proven to be associated with CSF or PET biomarkers and effectively discriminate AD from other neurodegenerative diseases. Our aim was to test their utility in clinical practice, from a multicentric unselected prospective cohort where patients presented with a large spectrum of cognitive deficits or complaints.
METHODS
The MEMENTO cohort enrolled 2,323 outpatients with subjective cognitive complaint (SCC) or mild cognitive impairment (MCI) consulting in 26 French memory clinics. Participants had neuropsychological assessments, MRI, and blood sampling at baseline. CSF sampling and amyloid PET were optional. Baseline blood Aβ42/40 ratio, total tau, p181-tau, and neurofilament light chain (NfL) were measured using a Simoa HD-X analyzer. An expert committee validated incident dementia cases during a 5-year follow-up period.
RESULTS
Overall, 2,277 individuals had at least 1 baseline blood biomarker available (n = 357 for CSF subsample, n = 649 for PET subsample), among whom 257 were diagnosed with clinical AD/mixed dementia during follow-up. All blood biomarkers but total tau were mildly correlated with their equivalence in the CSF (r = 0.33 to 0.46,
DISCUSSION
In a clinic-based cohort of patients with SCC or MCI, blood biomarkers may be good hallmarks of underlying pathology but add little to 5-year dementia risk prediction models including traditional predictors.
Identifiants
pubmed: 36261295
pii: WNL.0000000000201479
doi: 10.1212/WNL.0000000000201479
pmc: PMC9931079
doi:
Substances chimiques
Amyloid beta-Peptides
0
tau Proteins
0
Biomarkers
0
Peptide Fragments
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e473-e484Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Neurology. 2021 Aug 2;:
pubmed: 34341151
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
JAMA Neurol. 2021 Sep 1;78(9):1108-1117
pubmed: 34309632
Lancet Neurol. 2022 Jan;21(1):66-77
pubmed: 34838239
Sci Rep. 2016 May 31;6:26801
pubmed: 27241045
Lancet. 2021 Apr 24;397(10284):1577-1590
pubmed: 33667416
Curr Opin Neurol. 2021 Apr 1;34(2):266-274
pubmed: 33470669
Alzheimers Dement (Amst). 2022 Feb 09;14(1):e12266
pubmed: 35155728
Brain. 2021 Oct 22;144(9):2826-2836
pubmed: 34077494
JAMA Neurol. 2021 Nov 1;78(11):1307-1308
pubmed: 34515750
Cereb Cortex. 2009 Mar;19(3):497-510
pubmed: 18632739
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Neurology. 2019 Oct 22;93(17):e1647-e1659
pubmed: 31371569
J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):967-72
pubmed: 1431963
Alzheimers Dement. 2023 Jan;19(1):36-43
pubmed: 35235702
JAMA. 2020 Aug 25;324(8):772-781
pubmed: 32722745
Neuroinformatics. 2016 Jul;14(3):253-64
pubmed: 27066973
Acta Neuropathol. 2020 Sep;140(3):267-278
pubmed: 32720099
J Alzheimers Dis. 2018;62(4):1857-1863
pubmed: 29614646
Lancet Neurol. 2021 Jun;20(6):484-496
pubmed: 33933186
Nat Med. 2020 Mar;26(3):387-397
pubmed: 32123386
Sci Rep. 2021 May 6;11(1):9736
pubmed: 33958661
Lancet Neurol. 2010 Nov;9(11):1118-27
pubmed: 20934914
Nat Med. 2022 Oct 10;:
pubmed: 36216947
Lancet Neurol. 2021 Sep;20(9):739-752
pubmed: 34418401
Alzheimers Res Ther. 2016 Jun 06;8(1):22
pubmed: 27263933
Alzheimers Res Ther. 2022 Mar 29;14(1):46
pubmed: 35351181
Alzheimers Dement. 2021 Apr;17(4):641-652
pubmed: 33325121
Alzheimers Dement. 2021 Jul;17(7):1145-1156
pubmed: 33491853
Brain Commun. 2021 Feb 02;3(2):fcab008
pubmed: 33842885
Lancet Neurol. 2015 Jan;14(1):114-24
pubmed: 25496902
Alzheimers Res Ther. 2017 Aug 29;9(1):67
pubmed: 28851447
Nat Med. 2021 Jun;27(6):1034-1042
pubmed: 34031605
Alzheimers Res Ther. 2021 Dec 4;13(1):198
pubmed: 34863295
Nat Med. 2020 Mar;26(3):379-386
pubmed: 32123385
Ann Nucl Med. 2018 Feb;32(2):75-86
pubmed: 29218458
Alzheimers Dement. 2022 Dec;18(12):2669-2686
pubmed: 35908251
JAMA Neurol. 2019 May 1;76(5):598-606
pubmed: 30830207
Nature. 2018 Feb 8;554(7691):249-254
pubmed: 29420472
Acta Neuropathol. 2022 Apr;143(4):487-503
pubmed: 35195758
Nat Aging. 2021 Jan;1(1):114-123
pubmed: 37117993
Brain. 2021 Feb 12;144(1):325-339
pubmed: 33257949
Alzheimers Res Ther. 2021 Mar 25;13(1):65
pubmed: 33766131
Lancet Neurol. 2020 May;19(5):422-433
pubmed: 32333900
Alzheimers Res Ther. 2021 Dec 14;13(1):199
pubmed: 34906229
Alzheimers Dement. 2022 Jun;18(6):1128-1140
pubmed: 34569696
Alzheimers Dement. 2009 Jan;5(1):18-29
pubmed: 19118806
JAMA Neurol. 2017 May 1;74(5):557-566
pubmed: 28346578
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
EMBO Mol Med. 2021 Aug 9;13(8):e14398
pubmed: 34254442